Solvay No Longer Expects Advisory Cmte. For Irritable Bowel Drug Calmactin
This article was originally published in The Pink Sheet Daily
Executive Summary
Additional information submitted by company for the IBS agent was too voluminous to be completely reviewed prior to joint committee meeting tentatively set for March, Solvay suggests. FDA action on cilansetron NDA is still expected by April 1.